![]() ![]() Industrial pharmacist with a strategy background, I am an AI …By BioCentury Staff J11:56 PM UTC Alkerme s plc (NASDAQ:ALKS) won an arbitration tribunal with partner Johnson & Johnson (NYSE:JNJ) regarding the use of Alkermes’ NanoCrystal formulation technology across four J&J products, gaining $194 million in back royalties from 2022 and confirming the company will receive future royalties as. ![]() Associate Director, Business Development at PharmaronDiscovery, pre-clinical and CMC - EuropeDNA-encoded library (DEL) services - GlobalPassionate professional with proven successes in the life sciences industry including at a leading CRO and a VC-backed start-up. By BioCentury Staff J11:56 PM UTC Alkerme s plc (NASDAQ:ALKS) won an arbitration tribunal with partner Johnson & Johnson (NYSE:JNJ) regarding the use of Alkermes’ NanoCrystal formulation technology across four J&J products, gaining $194 million in back royalties from 2022 and confirming the company will receive future royalties as.Overall, the law makes Germany a less attractive. Two pharmas, Roche and AbbVie, are suing, saying that the legislation violates their rights. ![]() A law that went into effect in Germany in January financially stabilizes the country’s statutory health insurance system by mandating lower drug prices and higher rebates. ![]()
0 Comments
Leave a Reply. |